validated accepted marker mendrick explains lots biomarkers use never stringent trials notes industry setting process never lack precedent reflected regulatory void recently fda not established system approving pharmacogenomic products companies biomarkers house research years feared not validated fda refuse approve products based research concern conduct studies fda use says carol reed vice president medical affairs genaissance connecticut company developing gene based medicines diagnostics march fda produced long awaited guidance document clearly specifying kinds genomic data require drug approvals encouraging companies submit preliminary data voluntarily order help build scientific basis interpreting pharmacogenomic experiments agency working companies develop set guidelines define process